Bevacizumab in recurrent glioblastoma: open issues-Reference-Cited by-同舟云学术

Bevacizumab in recurrent glioblastoma: open issues

Published:2015-10 Issue:19 Volume:11 Page:2655-2665
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Franceschi Enrico¹,Bartolotti Marco¹,Brandes Alba A¹

Affiliation:

1. Department of Medical Oncology, Azienda USL, Bellaria Hospital – IRCCS Institute of Neurological Sciences, Bologna, Italy

Abstract

Recurrent glioblastoma represents a challenge in neuro-oncology since the prognosis is poor and current therapeutic options are limited. Bevacizumab has demonstrated activity in this setting in various clinical trials and has been approved by US FDA for the treatment of recurrent glioblastoma. Nevertheless, many issues still exist. In this article, we summarized the principal subjects of controversies that surround bevacizumab and its use in the treatment of recurrent glioblastoma.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon.15.125

Reference50 articles.

1. Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials

2. How effective is BCNU in recurrent glioblastoma in the modern era?: A phase II trial

3. Introduction

4. Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

5. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma;Neuro-Oncology Advances;2021-01-01

2. Current status of recurrent glioblastoma therapies;New Targeting in the Reversal of Resistant Glioblastomas;2021

3. Treatment response of bevacizumab combination chemotherapy in recurrent glioblastoma;Medicine;2020-02

4. Plasma and brain pharmacokinetics of letrozole and drug interaction studies with temozolomide in NOD-scid gamma mice and sprague dawley rats;Cancer Chemotherapy and Pharmacology;2018-10-24

5. Positron emission tomography imaging in gliomas: applications in clinical diagnosis, for assessment of prognosis and of treatment effects, and for detection of recurrences;European Journal of Neurology;2017-08-11